Place of Circulating Biomarkers and Respiratory Eicosanoids in the Prognosis of Severe Forms of Covid-19 Pneumonia

Covid19 Clinical Trial

— BIOCOVID  

Official title:

Place of Circulating Biomarkers and Respiratory Eicosanoids in the Prognosis of Severe Forms of Covid-19 Pneumonia: BioCovid Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04485364
• Other study ID #: BIOCOVID
• Status: Completed
• Start date: April 14, 2020
• Est. completion date: June 6, 2022

Study information

• Verified date: March 2023
• Source: Groupe Hospitalier Paris Saint Joseph
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The research is a prospective, multicentric (Groupe hospitalier Paris Saint-Joseph, Centre Hospitalier de Versailles André Mignot and Centre Hospitalier Victor Dupouy), non-interventional, prospective study. It aims at measuring eicosanoids at different stages of Covid-19 infection.

Description:

The reason for the involvement of overweight in the severity of viral respiratory pathologies, particularly during influenza and coronavirus infections, has been the subject of numerous studies which have made it possible to objectify the importance of viral load (at least in mice), particularly in the lower airways and in the alveolar sacs, leading to tissue alteration and alveolar haemorrhage. The mechanisms responsible for alveolar damage during viral pathologies, particularly Coronavirus, are very similar to those observed during acute respiratory distress syndromes in adults. In many situations, endotoxin (or lipopolysaccharide, LPS) plays a major role in the pathophysiology and even the severity of respiratory damage, in particular due to the existence of circulating endotoxin from the causative pathogen (Gram-negative bacteria), but also due to translocation of digestive origin in the context of sepsis (systemic inflammatory response) which is associated with (if not responsible for) respiratory aggression. The importance of this mechanism during pulmonary aggression of viral origin is however unknown. This respiratory attack is associated with a major systemic inflammatory response, reported during the course of Covid-19 infection as corresponding to a "cytokine storm". However, the course of the inflammation is poorly understood and its prognostic nature in the occurrence of a secondarily severe form is not yet better illustrated.

The inflammatory reaction (cytokines, eicosanoids, etc.) is an essential process for the elimination of pathogens by the host, but it must be limited in intensity and duration, otherwise it becomes deleterious for the infected organ. In the case of the lungs, it can induce an acute respiratory distress syndrome (ARDS), which can be severe as in Covid-19 patients with complications. It can be hypothesized that in the early stages of infection, these mediators may play a protective role against Covid-19. Inhibition of these mediators may therefore be deleterious as has been observed in subjects who have taken non-steroidal anti-inflammatory drugs (NSAIDs) that inhibit the production of eicosanoids.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 97
• Est. completion date: June 6, 2022
• Est. primary completion date: May 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient aged over 18 years

• French-speaking

• Patient whose Covid-19 respiratory infection was confirmed by laboratory tests, PCR and any other commercial or public health tests

• Patient hospitalized in intensive care unit and under invasive mechanical ventilation for less than three days (early inflammatory phase)

• Adult acute respiratory distress syndrome according to the Berlin definition

• Patient on long-term statin therapy regardless of the rationale for treatment (or without treatment for the control group).

Exclusion Criteria:

• Patient/family or "medical" proxy who refuses the patient's participation in the study

• Patient under guardianship or curatorship

• Patient deprived of liberty

• Patient under the safeguard of justice.

Related Conditions & MeSH terms

• Coronavirus
• COVID-19
• Covid19
• Pneumonia

Locations

Country	Name	City	State
France	Groupe Hospitalier Paris Saint-Joseph	Paris

Sponsors (3)

Lead Sponsor	Collaborator
Groupe Hospitalier Paris Saint Joseph	Centre Hospitalier Victor Dupouy, Versailles Hospital

Country where clinical trial is conducted

France, 

References & Publications (4)

Bradley BT, Bryan A. Emerging respiratory infections: The infectious disease pathology of SARS, MERS, pandemic influenza, and Legionella. Semin Diagn Pathol. 2019 May;36(3):152-159. doi: 10.1053/j.semdp.2019.04.006. Epub 2019 Apr 17. — View Citation

Fehr AR, Channappanavar R, Perlman S. Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus. Annu Rev Med. 2017 Jan 14;68:387-399. doi: 10.1146/annurev-med-051215-031152. Epub 2016 Aug 26. — View Citation

Vijayanand P, Wilkins E, Woodhead M. Severe acute respiratory syndrome (SARS): a review. Clin Med (Lond). 2004 Mar-Apr;4(2):152-60. doi: 10.7861/clinmedicine.4-2-152. — View Citation

Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018 Feb;23(2):130-137. doi: 10.1111/resp.13196. Epub 2017 Oct 20. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Inflammatory response in the evolution of respiratory diseases	The importance of the inflammatory response in the evolution of respiratory disease during the the patients' hospital care based on criteria such as: The search for systemic biomarkers: the previous work led by the Saint Joseph Hospital Group team has highlighted the potential interest of biomarkers of inflammation in the diagnosis of infectious pathology as well as in the eventual prognosis of these patients.; and the study of the production of eicosanoids and their presence in the systemic circulation and in the respiratory tree.	6 months = the study duration
Secondary	Impact of the respiratory disease during mechanical ventilation	Evolution of respiratory pathology during mechanical ventilation.	6 months = the study duration